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Purpose: Spinal muscular atrophy (SMA), caused by loss of the
SMN1 gene, is a leading cause of early childhood death. Due to the
near identical sequences of SMN1 and SMN2, analysis of this region
is challenging. Population-wide SMA screening to quantify the
SMN1 copy number (CN) is recommended by the American
College of Medical Genetics and Genomics.
Methods: We developed a method that accurately identifies the
CN of SMN1 and SMN2 using genome sequencing (GS) data by
analyzing read depth and eight informative reference genome
differences between SMN1/2.
Results: We characterized SMN1/2 in 12,747 genomes, identified
1568 samples with SMN1 gains or losses and 6615 samples with
SMN2 gains or losses, and calculated a pan-ethnic carrier frequency
of 2%, consistent with previous studies. Additionally, 99.8% of our
SMN1 and 99.7% of SMN2 CN calls agreed with orthogonal
methods, with a recall of 100% for SMA and 97.8% for carriers, and
a precision of 100% for both SMA and carriers.
Conclusion: This SMN copy-number caller can be used to identify
both carrier and affected status of SMA, enabling SMA testing to be
offered as a comprehensive test in neonatal care and an accurate
carrier screening tool in GS sequencing projects.
Genetics in Medicine (2020) 22:945–953; https://doi.org/10.1038/s41436-
020-0754-0
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INTRODUCTION
Spinal muscular atrophy (SMA), an autosomal recessive
neuromuscular disorder characterized by loss of alpha motor
neurons, causes severe muscle weakness and atrophy presenting
at or shortly after birth.1,2 SMA is the leading genetic cause of
infant death after cystic fibrosis.3 The incidence of SMA is 1 in
6000–10,000 live births, and the carrier frequency is 1:40–80
among different ethnic groups.4–7 Four clinical types of SMA
are classified based on age of onset and severity of the disease:1
very weak infants unable to sit unsupported (type I), weak
sitters but unable to stand (type II), ambulant patients with
weaker legs than arms (type III), and adult onset SMA (type
IV). Early detection of SMA can be critical for long term quality
of life due to the availability of two early treatments, nusinersen8
and Zolgensma,9 which have received FDA approval for the
amelioration of SMA symptoms.
The disease causing gene, SMN1, and its paralog SMN2,
reside in a ~2-Mb region on 5q with a large number of
complicated segmental and inverted segmental duplications.
SMN2 is 875 kb away from SMN1 and is created by an
ancestral gene duplication that is unique to the human
lineage.10,11 The genomic region around SMN1/2 is subject
to unequal crossing over and gene conversion, resulting in
variable copy numbers (CNs) of SMN1 and SMN2.7,12
Importantly, SMN2 has >99.9% sequence identity to SMN1
and one of the base differences, NM_000344.3:c.840C>T in
exon 7, has a critical functional consequence. By interrupting
a splicing enhancer, c.840T promotes skipping of exon 7,
resulting in the vast majority of SMN2-derived transcripts
(70–85%, depending on tissue13) being unstable and not fully
functional. Approximately 95% of SMA cases result from
biallelic absence of the functional c.840C nucleotide14 caused
by either a deletion of SMN1 or gene conversion to SMN2
(c.840T). In the remaining 5% of SMA cases, patients
also have other pathogenic variants in SMN1.15 SMN2 can
produce a small amount of functional protein, and the
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number of SMN2 copies in an individual modifies the disease
severity and is highly correlated with the clinical types
described above.16
Due to the high incidence rate and disease severity,
population-wide SMA screening is recommended by the
American College of Medical Genetics and Genomics.17 The
utility of population-wide carrier screening has been demon-
strated in pilot studies.18 The key to screening for SMA is (1)
determining the copy number of SMN1 for SMA diagnosis
and carrier testing and (2) determining the copy number of
SMN2 for clinical classification and prognosis. Traditionally,
SMA testing and carrier testing are done with polymerase
chain reaction (PCR) based assays, such as quantitative PCR
(qPCR),19 multiplex ligation-dependent probe amplification
(MLPA),20,21 and digital PCR.12,22 These methods primarily
determine the copy number of SMN1 based on the c.840C>T
site that differs between SMN1 and SMN2.
With recent advances in next-generation sequencing (NGS),
it is now possible to profile a large number of genes or even the
entire genome at high throughput and in a clinically relevant
timeframe. Driven by these advances, many countries are
undertaking large scale population sequencing efforts23–25
wherein testing for rare genetic disorders including carrier
status will be one of the primary drivers. Demonstrating that
GS can meet or exceed the performance of PCR-based SMA
tests would indicate that both current and future precision
medicine initiatives could leverage genome data for population-
level screening. Replicating the current SMA testing regime
poses a problem for high throughput GS due to the almost
perfect sequence identity between SMN1 and SMN2. Further-
more, it is thought that frequent gene conversion between
SMN1 and SMN2 leads to hybrid genes. These challenges
demand an informatics method specifically designed to
overcome the difficulties of this region.
To date, two NGS-based tests for SMA carrier detection
have been reported.26,27 Larson et al.26 used a Bayesian
hierarchical model to calculate the probability that the
fraction of SMN1-derived reads is equal to or smaller than
1/3 at three base differences between SMN1 and SMN2. Since
this method does not perform copy-number calling, it is not
an ideal solution for carrier screening. Conversely, Feng
et al.27 developed a copy-number caller for both SMN1 and
SMN2 based on targeted sequencing data that closely mimics
the current PCR-based method. Their method is designed for
targeted sequencing and thus requires specialized normal-
ization that limits their method to one assay at one site. More
importantly, the relatively low depths of GS (~30×) cannot
provide reliable bp-resolution CN calls (see Figure S1) and
since this method relies on a single locus, it is not amenable to
accurate CN calls with GS. Precision medicine initiatives will
need a way to diagnose and detect carriers of SMA from
GS data.
Here, we report a novel method that detects the CN of both
SMN1 and SMN2 using GS data. While most conventional
assays only test for the absence of c.840C as a proxy for the
“exon 7 deletion” (either a true deletion or as a product of
gene conversion with SMN2), here we describe a tool that can
more fully characterize the variability in the region including
(1) DNA deletions, including both whole-gene deletion/
duplication and a partial deletion of a region that includes
exons 7 and 8; and (2) small variant detection including the
NM_000344.3:c.*3+80T>G (also referred to as g.27134T>G
in literature) single-nucleotide polymorphism (SNP) that is
correlated with “silent” carriers of SMA (two copies of SMN1
on the same haplotype).28 To demonstrate the accuracy of this
method, we compared CN calls using digital PCR and MLPA
with our GS-based calls and showed a concordance of 99.8%
for SMN1 and 99.7% for SMN2. Additionally, we applied this
method to 2504 unrelated samples from the 1000 Genomes
Project29 (1kGP) and 10,243 unrelated samples from the
NIHR BioResource Project (The NIHR BioResource, in
revision) to report on the population distributions of SMN1
and SMN2 copy numbers. The carrier frequencies for SMA
using this method agreed with those reported by previous
PCR-based studies.5,6 In addition to demonstrating the
accuracy of our method to quantify variants in the SMN
region, we also highlight the importance of using ethnically
diverse populations when developing novel informatic
methods to resolve difficult clinically relevant regions of the
genome.
MATERIALS AND METHODS
Samples and data processing
Samples validated using digital PCR were procured from the
Motor Neuron Diseases Research Laboratory (Nemours
Alfred I. duPont Hospital for Children) collection and were
generated from cell lines as described previously.12,30
Historical patient samples with known SMA or carrier status
measured by MLPA were obtained from Cambridge Uni-
versity. GS was performed on 73 samples with digital PCR
results, 45 samples with MLPA results, and 12,747 population
samples from the 1000 Genomes Project29 (1109 of which
have MLPA calls), the National Institute for Health Research
(NIHR) BioResource Rare Diseases project and the Next
Generation Children (NGC) project.31 The sequencing and
processing of this data was done using a variety of sample
preparation methods, Illumina sequencers, and read aligners.
A full description of this data can be found in the
Supplementary Methods.
SMN copy-number analysis by orthogonal methods
SMN1 and SMN2 CNs were measured for 73 samples using
the QuantStudio 3D Digital PCR System (Life Technologies)
using allele-specific exon 7 probes as described previously.12
SMN1 and SMN2 copy numbers were normalized against
those for RPPH1 (RNase P). MLPA CN calls for 1109 of the
1kGP samples were available from Vijzelaar et al.32 Forty-five
historical patient samples were previously tested in a clinically
accredited laboratory by MLPA for SMN1/2 exons 7 and 8
copy number (SALSA MLPA P060 SMA Carrier probemix,
MRC-Holland). Additionally, two samples from the Next
Generation Children project were confirmed using MLPA.
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Copy-number calling for intact and truncated SMN
Two common copy-number variants (CNVs) involve the
SMN1 and SMN2 loci, the whole-gene CNV, and a partial
gene deletion of exons 7 and 8 (SMN2Δ7–8)32,33 (see
“Results”). We first count reads that align to either SMN1
or SMN2. Read counts in a 22.2-kb region encompassing exon
1 to exon 6 are used to calculate the total SMN (SMN1, SMN2,
and SMN2Δ7–8) CN, and read counts in the 6.3-kb region
including exons 7 and 8 are used to calculate the CN of intact
SMN (SMN1 and SMN2). Read counts are normalized and
converted into copy numbers using a one-dimensional
mixture of Gaussian distributions (see Supplementary Infor-
mation). The copy number of truncated SMN (SMN2Δ7–8)
is derived by subtracting the intact SMN CN from total
SMN CN.
Genotyping SMN1/2 copy number using differentiating
bases
We call the number of chromosomes carrying the SMN1 and
SMN2 bases by combining the total SMN CN with the read
counts supporting each of the gene-specific bases. At each
SMN1/2 differentiating base (Table S1), based on the called
copy number of intact SMN, the caller iterates through all
possible combinations of SMN1 and SMN2 copy numbers and
derives the combination that produces the highest posterior
probability for the observed number of SMN1 and SMN2
supporting reads. The SMN1 CNs called at single bases are
then combined to make the aggregate SMN1 CN call based on
a consensus rule (see Supplementary Methods). In addition to
calling the CN of bases that are specific to either SMN1 or
SMN2, this method can be applied to variant positions to
identify the copy number of bases known to be specific to one
of the two genes, e.g., c.*3+80T>G as described in “Results”.
Ethics approval and consent
The 13,343 individuals from the NIHR BioResource Rare
Diseases project were recruited through NHS Cambridge
University Hospitals Foundation Trust under Cambridge
South Research Ethics Committee approval 13/EE/0325.
The 65 patient-derived DNA samples from the Motor
Neuron Diseases Research Laboratory were isolated from
established fibroblast or lymphoblastoid cell lines. For those
cell lines obtained from noncommercial sources, biospeci-
mens were obtained after written consent or assent and
parental permission. This study was approved by the
Nemours/Alfred I. duPont Hospital for Children Institutional
Review Board. These samples were de-identified so that no
protected health information is known for these lines.
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Fig. 1 Common copy-number variants (CNVs) affecting the SMN1/2 loci. a Depth profiles across the SMN1/SMN2 regions. Samples with a total
SMN1+ SMN2 copy number of 2, 3, 4, and 5 (derived from average read depth in the two genes) are shown as green, blue, black, and orange dots,
respectively. Depth from 50 samples are summed up for each CN category. Each dot represents normalized depth values in a 100-bp window. Read counts
are calculated in each 100-bp window, summing up reads from both SMN1 and SMN2, and normalized to the depth of wild-type samples (CN= 4). The
SMN exons are represented as purple boxes. The two x-axes show coordinates (hg19) in SMN1 (bottom) and SMN2 (upper). b Depth profiles aggregated
from 50 samples carrying a deletion of exons 7 and 8 are shown as red dots. Read depths are calculated in the same way as in (a).
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RESULTS
Common CNVs involving the SMN1/2 loci
While existing PCR- or NGS-based methods focus primarily
on the c.840C>T site, we adopted a copy-number approach
based on the sequencing data from the full genes. We
examined the read depth across the ~30-kb homologous
region harboring SMN1 and SMN2 genes in 1kGP samples
(Fig. 1a). The depth profile shows that this entire region can
be deleted or duplicated in the population. The exact
breakpoints of this CNV are expected to vary from sample
to sample due to the extensive sequence homology within and
beyond this region and can only be resolved in high resolution
with long read sequencing. We restricted our CN analysis to
the (~30 kb) regions that include the SMN genes (SMN1 or
SMN2).
In addition to whole-gene CNVs, we also found a 6.3-kb
partial gene deletion encompassing both exons 7 and 8
(Fig. 1b, Figure S2) that was recently described in another
study.33 The sequences at the breakpoint are identical
between SMN1 and SMN2, so this deletion occurs at
either chr5: 70244114–70250420 in SMN1 or chr5:
69368689–69375000 in SMN2 (Figure S2, hg19). However,
about 500 bp downstream from the breakpoint that defines
the end of this deletion there are three base differences
between the SMN1 and SMN2 loci (70250881A>69375425C,
70250981A>69375525G, 70250991A>69375535G). Among
the 1kGP samples that contain this deletion, we identified
245 read pairs from 237 samples where one spanned the
breakpoint and the mate spanned at least two of the three
SMN-differentiating bases. Analysis of these read pairs
revealed that 100% were consistent with the deletion
occurring on the SMN2 sequence background. We named
this truncated form of SMN2 “SMN2Δ7–8”. Since both
exons 7 and 8 are deleted, SMN2Δ7–8 most likely has
limited or no biological function. Therefore, SMN2Δ7–8 is
an important variant that any SMN CN caller should take
into account.
After searching for anomalous read pairs in the 1kGP
samples, we did not identify any other common CNVs in the
SMN region. Combining this information together, we called
CNs of the SMN genes to specifically identify the number of
intact and truncated forms by dividing the genes into two
regions: the 6.3-kb region that includes exons 7–8 and the
22.2-kb region that includes exons 1–6. The CN calculated
from the exon 7–8 region provided the number of intact SMN
genes. Samples with SMN2Δ7–8 have a higher CN call from
the exon 1–6 region compared with the CN call from the exon
7–8 region, and this difference represents the CN of
SMN2Δ7–8. Figure 2 shows the results of this calculation
for 12,747 samples where we identified 2144 instances of
SMN2Δ7–8 including 140 samples with two copies of
SMN2Δ7–8 and one sample with three copies of SMN2Δ7–8.
SMN1/2 CN calls using differentiating bases
We called the CNs of SMN1 and SMN2 at the 16 base
difference sites between SMN1 and SMN2 (see “Materials and
Methods”, Table S1) in 1kGP samples, and compared the CN
calls for each position with the CN calls at the splice variant
site (Fig. 3a, Figure S3). There was a notable difference
between the concordance of calls in the African and non-
African populations (Fig. 3a). Excluding the African samples,
there were 13 sites that had high (>85%) CN concordance
with the splice variant site. Conversely, for the African
samples there were only seven sites that had high CN
concordance with the splice variant site, and the concordance
values were lower than in non-African populations. This is
consistent with within-gene variation at many of these
positions in the African population. We selected the splice
variant site and the seven positions that were highly
concordant with the splice variant site in both African and
non-African populations to make SMN1 and SMN2 CN calls
based on the consensus of CN calls at the selected sites (see
Supplementary Information for the detailed rules and in-
depth analysis on the variability of the 16 sites).
Validation of the SMN copy-number caller
After developing this method, we tested its accuracy against
results from orthogonal methods. We sequenced 73 samples
with known SMN1 and SMN2 CNs measured by digital PCR;
45 samples with known results measured by MLPA; and also
compared our CN calls with MLPA calls published by
Vijzelaar et al.33 on 1109 samples from the 1kGP. These
validation data include 64 SMA probands, 45 SMA carriers,
and 1118 samples with an SMN1 CN larger than 1. Our SMN1
CN calls agreed with digital PCR results in 99.8% of the
samples, the SMN2 CN calls agreed in 99.7% of the samples,
and SMN2Δ7–8 calls agreed in 100% of the samples (Table 1,
Table S2). Combined, our recall is 100% for SMA (SMN1
CN= 0, 64/64), 97.8% for carriers (SMN1 CN= 1, 44/45, the
one missed carrier does not show read evidence supporting














Fig. 2 Scatterplot of total SMN (SMN1, SMN2, and SMN2Δ7–8) copy
number (CN) (x-axis, called by read depth in exons 1–6) and intact SMN
copy number (y-axis, called by read depth in exons 7–8).
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precision is 100% for both SMA (1160/1160) and carriers
(1179/1179). We also analyzed the consistency of SMN1/
SMN2/SMN2Δ7–8 CN calls in 258 trios from the Next
Generation Children project cohort. There is no Mendelian
error in any of the calls (Table S3).
Further inspection of the five discrepant samples does not
show evidence of errors in our calls except in one sample
(see Supplementary Information). The validation for the
73 and 45 samples was done using two sets of probes
targeting exons 7 and 8 of SMN1 and SMN2, while the
validation for the 1109 samples used a newer version of
the MLPA probemix that includes an additional 17 probes
used to determine the SMN1+ SMN2 CN in exons 1–6 and
exons 7–8, which helped refine the individual SMN1 and
SMN2 CN calls. Correspondingly our concordance is
significantly higher (p value= 0.009223 for SMN1, 2.651e-
05 for SMN2, Fisher’s exact test) measured against the
newer version of MLPA (100% concordance for SMN1 and









































































































Fig. 3 Distribution of SMN1/SMN2/SMN2Δ7–8 copy numbers in the population. a Percentage of samples showing copy number (CN) call agreement
with c.840C>T across 16 SMN1–SMN2 base difference sites in African and non-African populations. Coordinates of these 16 sites are given in Table S1 and
site 13* is the c.840C>T splice variant site. The black horizontal line denotes 85% concordance. b Histogram of the distribution of SMN1, SMN2, and
SMN2Δ7–8 copy numbers across five populations in 1kGP and the National Institute for Health Research (NIHR) BioResource cohort. c SMN1 CN vs. total
SMN2 CN (intact SMN2+ SMN2Δ7–8). d Two trios with an SMA proband detected by the caller and orthogonally confirmed in the Next Generation
Children project cohort. CNs of SMN1, SMN2, and SMN2Δ7–8 are phased and labeled for each member of the trios.
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Copy number of SMN1, SMN2, and SMN2Δ7–8 by
population
Given the high accuracy demonstrated by our validation
against orthogonal methods, we next applied this method to
high depth (all samples sequenced to at least 30×) GS data
from 12,747 unrelated samples from the 1kGP and the NIHR
BioResource Project (Table S4). We analyzed the CN
distributions by population (Europeans, Africans, East Asians,
South Asians, and admixed Americans consisting of Colom-
bians, Mexican Americans, Peruvians, and Puerto Ricans).
Figure 3b shows the histogram of the number of individuals
with different CNs of intact SMN1, intact SMN2, and
SMN2Δ7–8. The distributions are similar between the 1kGP
samples and the NIHR BioResource samples (Figure S4,
Table S5). In general, individuals have more copies of SMN1
than SMN2. The most common combinations of SMN1/
SMN2 copy number are 2/2 (44.9%) and 2/1 (33.4%). The
variability of SMN1 copy number is much lower than that of
SMN2 copy number in most populations, while the Africans
show higher variability in both SMN1 and SMN2 CN.
Conversely, 54.7% of Africans have three or more copies of
SMN1, which is more than double what is observed in any of
the other four populations (Fig. 3b, Table 2). There is an
inverse relationship between the copy number of SMN1 and
SMN2 (Fig. 3c, correlation coefficient -0.344, p value <2.2e-
16). This observation is consistent with a mechanism where
gene conversion occurs between SMN1 and SMN2.34,35 The
observed higher SMN1 CN relative to SMN2 CN could be a
result of a bias toward SMN2-to-SMN1 conversion or
selection against a low SMN1 CN. Africans have significantly
lower SMN2 CN than the other populations (Wilcoxon test,
p value < 2.2e-16).
The number of SMA carriers identified across populations
is summarized in Table 2 and Table S6. In 12,683
individuals with confident SMN1/SMN2 CN calls, Eur-
opeans have the highest carrier frequency at 2.2%, followed
by admixed Americans (2.05%), South Asians (1.67%),
and East Asians (1.35%). Africans have the lowest
carrier frequency (0.44%) by SMN1 CN, and this carrier
frequency does not include the 2+ 0 SMA silent
carriers that are more common in Africans (see “Detection
of ‘silent’ carriers”). The CN frequency distributions
observed in this study are consistent with previous studies
of SMN1/SMN2 CN distribution in the general
population.5,6 In addition, we also report the frequency of
the exon 7–8 deletion (SMN2Δ7–8) across populations:
21.2% of Europeans and 11.5% of admixed Americans have
at least one copy of SMN2Δ7–8, while the frequency is lower
Table 1 Validation against samples with known SMN1/SMN2 copy numbers (CNs).
CN by orthogonal method Total Concordant Discordant Agreement
SMN1 0 64 64 0 100.0%
1 45 44 1 97.8%
2 897 897 0 100.0%
3 174 174 0 100.0%
4 43 43 0 100.0%
6 1 0 1 0.0%
Total 1224 1222 2 99.8%
SMN2 0 117 117 0 100.0%
1 466 465 1 99.8%
2 541 539 2 99.6%
3 60 60 0 100.0%
4 9 8 1 88.9%
Total 1193 1189 4 99.7%
SMN2Δ7–8 0 1089 1089 0 100.0%
1 80 80 0 100.0%
2 4 4 0 100.0%
Total 1173 1173 0 100.0%
Table 2 SMN1 copy number (CN) and c.*3+80T>G frequency by population.
Ethnicity Total SMN1 CN= 1 SMN1 CN= 2 SMN1 CN= 3 SMN1 CN= 4
Count c.*3+80T>G+ Count c.*3+80T>G+ Count c.*3+80T>G+ Count c.*3+80T>G+
African 902 4 0 (0.0%) 404 134 (33.2%) 373 315 (84.5%) 121 112 (92.6%)
European 9648 212 0 (0.0%) 8899 4 (0.04%) 524 22 (4.2%) 13 2 (15.38%)
South Asian 1199 20 0 (0.0%) 965 1 (0.1%) 195 5 (2.56%) 19 1 (5.26%)
East Asian 593 8 0 (0.0%) 552 1 (0.18%) 33 1 (3.03%) 0 0 (NA)
Admixed American 341 7 0 (0.0%) 296 7 (2.36%) 36 9 (25.0%) 2 1 (50.0%)
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in South Asians (3.35%), Africans (1.1%), and East Asians
(0.34%).
In the Next Generation Children project cohort, we
identified SMA in two neonatal probands from trio analysis,
which were confirmed independently. SMN1, SMN2, and
SMN2Δ7–8 CNs are phased for each trio member (Fig. 3d).
Detection of “silent” carriers
The c.*3+80T>G SNP has been reported to be associated
with the 2+ 0 SMA silent carrier status where one
chromosome carries two copies of SMN1 (either by SMN1
duplication or gene conversion of SMN2 to SMN1) and the
other chromosome has no copies of SMN1.28 Our method can
also detect the presence of this SNP and thus can be used to
screen for potential silent carriers. In the population samples,
this SNP is differentially associated with two-copy and one-
copy SMN1 haplotypes and can be used to identify silent
carriers (Table 2). We estimate the sensitivity improvement
(with the biggest improvement from 70.5% to 91.8% in
Africans) and residual risks for calling SMA carriers using the
combination of SMN1 CN and c.*3+80T>G SNP calling (see
Supplementary Information, Table S7, Table S8). One of our
validation samples is a silent carrier and we correctly called
SMN1 CN= 2 and the presence of c.*3+80T>G SNP
(Table S2).
DISCUSSION
Due to the high sequence homology between SMN1 and
SMN2, the SMN region is difficult to resolve with both short
and long read sequencing and thus far this important region
has been excluded from standard GS analysis. Here, we
demonstrate an algorithm that can resolve the CNs of SMN1
and SMN2 independently using short-read GS data, filling in
an important gap in SMA diagnosis and carrier screening for
precision medicine initiatives. Accurate measurement of
SMN1 and SMN2 CNs is essential not only for the diagnosis
of SMA but is also a prognostic indicator and the basis of
therapeutic options.36 SMN2 CN has been used as a criterion
for many clinical trials for SMA, including nusinersen8 and
Zolgensma.9
As a demonstration of this algorithm, we made CN calls for
SMN1 and SMN2 using sequencing data from 12,747 samples
covering five distinct subpopulations. We identified a total of
251 samples with SMN1 losses (less than two copies) and 1317
with SMN1 gains (more than two copies), 6241 samples with
SMN2 losses and 1274 with SMN2 gains, and 2144 samples
carrying one or more copies of the truncated form
SMN2Δ7–8. We cannot quantify the role that deletions,
duplications, or gene conversion play to drive the CN changes
in this region but we see evidence supporting all three
mechanisms including (1) 3853 samples with total (SMN1+
SMN2) CN <4 (deletions), (2) 670 samples with total CN >4
(duplications), and (3) a strong inverse correlation between
the SMN1 and SMN2 CN (gene conversion, Fig. 3c).
Additionally, we identified a carrier frequency between 1:45
and 1:225 depending on ancestral population (Table 2).
Comparing the CN frequencies by population shows that they
are highly different and our per-population results agree with
previous population studies.5,6 While this provides qualitative
support for the accuracy of our method, we also directly
assessed its accuracy by comparing our CN calls against the
results from digital PCR or MLPA. In this direct comparison,
99.8% of our SMN1 and 99.7% of our SMN2 CN calls agreed
with the digital PCR-based or MLPA-based results. Impor-
tantly, our recall is 100% for SMA and 97.8% for carriers, and
our precision is 100% for both SMA and carriers.
In this study, we optimized our CN calling to work for
individuals of any ancestry and thus limited SMN1/2
differentiation to the functionally important splice variant
plus seven sites in high concordance with the splice variant
across all populations (Fig. 3a). By quantifying the con-
cordance between all of the reference differences and the
splice variant, we were able to identify variations at these sites
that, if not accounted for properly (i.e., removed from our
analysis), could lead to errors in our CN calls. This would be
especially problematic in analyzing Africans because they
harbor more diverse haplotypes. Future population genetic
studies, possibly including using long read sequencing, will
help profile the haplotypic diversity across populations more
directly and identify new variant sites that could further
improve the accuracy of SMN1/SMN2 differentiation.
An important area for improvement is the detection of
“silent” carriers. One type of silent carrier occurs when an
individual has two copies of the SMN1 gene but they are both
on the same haplotype. A SNP (c.*3+80T>G) has been used
to identify individuals who are at an increased risk of being
carriers when SMN1 CN is two but the risk associated with
this SNP can vary greatly between studies and populations
(Table S7, Table S8). When an individual has just one copy of
SMN1 they can be definitively identified as a carrier, but this
variant only indicates a 2–8% chance of being a carrier when
SMN1 CN is two (Table S8). With GS, it would be possible to
catalog the different variants that occur with different CN
combinations of SMN1 and SMN2 and possibly identify
additional markers that could be used to improve our ability
to identify these silent carriers. In addition, the loss of the
c.840C splice variant currently explains around 95% of SMA
cases and the remaining cases include other pathogenic
variants. These other pathogenic variants represent another
type of silent carrier and as more of them are identified, we
will extend this software to directly genotype these as part of
the testing process, further improving the ability to detect
SMA carriers and cases.
While there exist difficult regions in the genome where
normal GS pipelines do not deliver variant calls, here we
demonstrate the ability to apply GS paired with a targeted
informatics approach to solve one such difficult region. So far,
this targeted strategy (GS+ specialized informatics) has been
applied successfully to a number of difficult variants, such as
repeat expansions37 and CYP2D6.38 Traditionally, it is not
cost effective to perform all of the known genetic tests and
carrier screenings on every individual, so candidates for
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specific genetic testing are identified using information such
as the carrier rate and family history. However, this process
means that many people without a family history who would
benefit from knowing their SMA status do not routinely have
access to this data. Once GS analysis can detect all single-
nucleotide variants (SNVs) and CNVs in all clinically relevant
genes accurately then a more general and population-wide
genetic testing strategy will be feasible with a single test.
Improving GS to become economical as a substitute for one
current genetic test will help facilitate the integration of more
genetic tests and carrier screens into GS, allowing more
general access to genetic testing population-wide. GS provides
a valuable opportunity to assess the entire genome for genetic
variation and the continued development of more targeted
informatics solutions for difficult regions with GS data will
help bring the promise of personalized medicine one step
closer to reality.
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SOFTWARE AND DATA AVAILABILITY
The SMN copy-number caller described here can be downloaded
from https://github.com/Illumina/SMNCopyNumberCaller.
The 1kGP data can be downloaded from https://www.ncbi.nlm.
nih.gov/bioproject/PRJEB31736/. Data from the NIHR BioResource
participants have been deposited in European Genome-phenome
Archive (EGA) at the EMBL European Bioinformatics Institute
(accession codes available at https://www.biorxiv.org/content/
10.1101/507244v1). Those participants from the NIHR BioRe-
source who enrolled for the 100,000 Genomes Project–Rare
Diseases Pilot can be accessed by seeking access via Genomics
England Limited following the procedure outlined at https://
www.genomicsengland.co.uk/about-gecip/joining-research-
community. The Bam files from the NGC individuals have been
deposited in EGA under accession number EGAD00001004357.
ACKNOWLEDGEMENTS
This work was supported by the Cambridge Biomedical Research
Centre and the NIHR for the NIHR BioResource (grant number
RG65966), the National Institute of General Medical Sciences
of the National Institutes of Health (P30GM114736 and
P20GM103446; to M.E.R.B.) and the Nemours Foundation (to
M.E.R.B.). We thank the New York Genome Center (supported
by National Human Genome Research Institute grant
3UM1HG008901–03S1), and the Coriell Institute for Medical
Research for generating and releasing the 1kGP GS data. We
thank NIHR BioResource volunteers for their participation, and
gratefully acknowledge NIHR BioResource centers, NHS Trusts,
and staff for their contribution. We thank the NIHR and NHS
Blood and Transplant. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR, or the
Department of Health and Social Care.
DISCLOSURE
X.C., Z.K., A.C., A.L.H., R.J.T., D.R.B. and M.A.E. are employees of
Illumina Inc. The other authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard
to jurisdictional claims in published maps and institutional
affiliations.
REFERENCES
1. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:
2120–2133.
2. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy:
controversies and challenges. Lancet Neurol. 2012;11:443–452.
3. Prior TW. Perspectives and diagnostic considerations in spinal muscular
atrophy. Genet Med. 2010;12:145–152.
4. Ogino S, Leonard DGB, Rennert H, Ewens WJ, Wilson RB. Genetic risk
assessment in carrier testing for spinal muscular atrophy. Am J Med
Genet. 2002;110:301–307.
5. Hendrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1
allele frequencies among ethnic groups within North America. J Med
Genet. 2009;46:641–644.
6. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and
prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis
of >72 400 specimens. Eur J Hum Genet. 2012;20:27–32.
7. MacDonald WK, Hamilton D, Kuhle S. SMA carrier testing: a meta-
analysis of differences in test performance by ethnic group. Prenat Diagn.
2014;34:1219–1226.
8. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal
muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation
study. Lancet. 2016;388:3017–3026.
9. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement
therapy for spinal muscular atrophy. N Engl J Med. 2017;377:
1713–1722.
10. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and
characterization of a spinal muscular atrophy-determining gene. Cell.
1995;80:155–165.
11. Rochette CF, Gilbert N, Simard LR. SMN gene duplication and the
emergence of the SMN2 gene occurred in distinct hominids: SMN2 is
unique to Homo sapiens. Hum Genet. 2001;108:255–266.
12. Stabley DL, Harris AW, Holbrook J, et al. SMN1 and SMN2 copy
numbers in cell lines derived from patients with spinal muscular
atrophy as measured by array digital PCR. Mol Genet Genomic Med.
2015;3:248–257.
13. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the
SMN gene regulates splicing and is responsible for spinal muscular
atrophy. Proc Natl Acad Sci USA. 1999;96:6307–6311.
14. Wirth B. An update of the mutation spectrum of the survival motor
neuron gene (SMN1) in autosomal recessive spinal muscular atrophy
(SMA). Hum Mutat. 2000;15:228–237.
15. Burghes AHM, Beattie CE. Spinal muscular atrophy: why do low levels of
SMN make motor neurons sick? Nat Rev Neurosci. 2009;10:597–609.
16. Butchbach MER. Copy number variations in the survival motor
neuron genes: implications for spinal Muscular atrophy and other
neurodegenerative diseases. Front Mol Biosci. 2016;3:7
17. Prior TW. Carrier screening for spinal muscular atrophy. Genet Med.
2008;10:840–842.
18. Kraszewski JN, Kay DM, Stevens CF, et al. Pilot study of population-based
newborn screening for spinal muscular atrophy in New York state. Genet
Med. 2018;20:608–613.
19. Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative
analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and
highly reliable carrier testing and prediction of severity of spinal muscular
atrophy. Am J Hum Genet. 2002;70:358–368.
20. Arkblad EL, Darin N, Berg K, et al. Multiplex ligation-dependent probe
amplification improves diagnostics in spinal muscular atrophy.
Neuromuscul Disord. 2006;16:830–838.
21. Scarciolla O, Stuppia L, De Angelis MV, et al. Spinal muscular atrophy
genotyping by gene dosage using multiple ligation-dependent probe
amplification. Neurogenetics. 2006;7:269–276.
22. Zhong Q, Bhattacharya S, Kotsopoulos S, et al. Multiplex digital PCR:
breaking the one target per color barrier of quantitative PCR. Lab Chip.
2011;11:2167–2174.
ARTICLE CHEN et al
952 Volume 22 | Number 5 | May 2020 | GENETICS in MEDICINE
23. Ashley EA. The Precision Medicine Initiative: a new national effort. JAMA.
2015;313:2119–2120.
24. The Genome of the Netherlands Consortium, Francioli LC, Menelaou A,
et al. Whole-genome sequence variation, population structure and
demographic history of the Dutch population. Nat Genet. 2014;46:
818–825.
25. Turnbull C, Scott RH, Thomas E, et al. The 100 000 Genomes Project:
bringing whole genome sequencing to the NHS. BMJ. 2018;361:k1687.
26. Larson JL, Silver AJ, Chan D, Borroto C, Spurrier B, Silver LM. Validation of
a high resolution NGS method for detecting spinal muscular atrophy
carriers among phase 3 participants in the 1000 Genomes Project. BMC
Med Genet. 2015;16:100.
27. Feng Y, Ge X, Meng L, et al. The next generation of population-based
spinal muscular atrophy carrier screening: comprehensive pan-ethnic
SMN1 copy-number and sequence variant analysis by massively parallel
sequencing. Genet Med. 2017;19:936–944.
28. Luo M, Liu L, Peter I, et al. An Ashkenazi Jewish SMN1 haplotype specific
to duplication alleles improves pan-ethnic carrier screening for spinal
muscular atrophy. Genet Med. 2014;16:149–156.
29. The 1000 Genomes Project Consortium. A global reference for human
genetic variation. Nature. 2015;526:68–74.
30. Stabley DL, Holbrook J, Harris AW, et al. Establishing a reference dataset
for the authentication of spinal muscular atrophy cell lines using STR
profiling and digital PCR. Neuromuscul Disord. 2017;27:439–446.
31. French CE, Delon I, Dolling H, et al. Whole genome sequencing reveals
that genetic conditions are frequent in intensively ill children. Intensive
Care Med. 2019;45:627–636.
32. Vijzelaar R, Snetselaar R, Clausen M, et al. The frequency of SMN gene
variants lacking exon 7 and 8 is highly population dependent. PLoS One.
2019;14:e0220211.
33. Ruhno C, McGovern VL, Avenarius MR, et al. Complete sequencing of
the SMN2 gene in SMA patients detects SMN gene deletion junctions
and variants in SMN2 that modify the SMA phenotype. Hum Genet.
2019;138:241–256.
34. Ogino S, Gao S, Leonard DGB, Paessler M, Wilson RB. Inverse correlation
between SMN1 and SMN2 copy numbers: evidence for gene conversion
from SMN2 to SMN1. Eur J Hum Genet. 2003;11:275.
35. Chen T-H, Tzeng C-C, Wang C-C, et al. Identification of bidirectional
gene conversion between SMN1 and SMN2 by simultaneous analysis of
SMN dosage and hybrid genes in a Chinese population. J Neurol Sci.
2011;308:83–87.
36. Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of
spinal muscular atrophy: part 1: recommendations for diagnosis,
rehabilitation, orthopedic and nutritional care. Neuromuscul Disord.
2018;28:103–115.
37. Dolzhenko E, van Vugt JJFA, Shaw RJ, et al. Detection of long repeat
expansions from PCR-free whole-genome sequence data. Genome Res.
2017;27:1895–1903.
38. Lee S, Wheeler MM, Patterson K, et al. Stargazer: a software tool for
calling star alleles from next-generation sequencing data using CYP2D6
as a model. Genet Med. 2019;21:361.
Open Access This article is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0 International
License, which permits any non-commercial use, sharing, distribution and
reproduction in any medium or format, as long as you give appropriate credit to
the original author(s) and the source, and provide a link to the Creative
Commons license. You do not have permission under this license to share
adaptedmaterial derived from this article or parts of it. The images or other third
party material in this article are included in the article’s Creative Commons
license, unless indicated otherwise in a credit line to thematerial. Ifmaterial is not
included in the article’s Creative Commons license and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to
obtain permission directly from the copyright holder. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
© The Author(s) 2020
CHEN et al ARTICLE
GENETICS in MEDICINE | Volume 22 | Number 5 | May 2020 953
